Changing serological status and low vaccination-induced protection rates against hepatitis B characterize chronic hepatitis C virus-infected injecting drug users in Greece: Need for immunization policy

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 11, 2006, Pages 1227-1231

  Elefsiniotis, Ioannis S ^a,d   Pantazis, Konstantinos D ^a   Ketikoglou, Ioannis D ^a   Koutsounas, Sotirios I ^b   Tsianos, Epameinondas V ^c  

^a HIPPOKRATION HOSPITAL   (Greece)

^b National Centre for Viral Hepatitis   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d NONE   (Greece)

Author keywords

Hepatitis B; Hepatitis B virus vaccination; Hepatitis C; Injecting drug use

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC TEST; FEMALE; GENOTYPE; GREECE; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STUDENT T TEST; VACCINATION;

ADULT; ANTIBODIES, VIRAL; CHI-SQUARE DISTRIBUTION; FEMALE; GENOTYPE; GREECE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNIZATION PROGRAMS; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; SEROLOGIC TESTS; SUBSTANCE ABUSE, INTRAVENOUS; TIME;

EID: 33749836362     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.meg.0000236888.51838.36     Document Type: Article

References (23)

1. Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis 2002; 185:713-719.
2. Kwiatkowski CF, Corsi KF, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 2002; 97:1289-1294.
3. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral and environmental factors. JAMA 2000; 284:450-456.
4. Mc Gregor J, Marks PJ, Hayward A, Bell Y, Slack RCB. Factors influencing hepatitis B vaccine uptake in injecting drug users. J Public Health Med 2003; 25:165-170.
5. Estrada AL. Epidemiology of HIV/AIDS, hepatitis B, hepatitis C and tuberculosis among minority injection drug users. Public Health Rep 2002; 117 (Suppl 1):S126-S134.
6. Santolamazza M, Delle Monache M, Alvino A, Bacosi M, D'Innocenzo S, Ciervo U, et al. Multiple viral infections in a group of intravenous drug users: hepatitis B virus exposure is the risk factor. Eur J Gastroenterol Hepatol 2001; 13:1347-1354.
7. Stamouli M, Gizaris V, Totos G, Papaevangelou G. Decline of hepatitis B infection in Greece. Eur J Epidemiol 1999; 15:447-449.
8. Roumeliotou-Karayiannis A, Tassopoulos N, Karpodini E, Trichopoulou E, Kotsianopoulou M, Papaevangelou G. Prevalence of HBV, HDV and HIV infections among intravenous drug addicts in Greece. Eur J Epidemiol 1987; 3:143-146.
9. Papaevangelou G. Hepatitis B immunization programme: lessons learnt in Greece. Vaccine 1998; 16:S45-S47.
10. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
11. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity and response to interferon therapy. Ann Intern Med 1996; 125:634-639.
12. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997; 26:485-490.
13. Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998; 28:562-567.
14. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32:582-587.
15. Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, Smoak BL, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132:105-111.
16. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340:1228-1233.
17. Rai R, Wilson LE, Astemborski J, Anania F, Torbenson M, Spoler C, et al. Severity and correlates of liver disease in hepatitis C virus infected injection drug users. Hepatology 2002; 35:1247-1255.
18. Idilman R, De Maria N, Colantoni A, Nadir A, Van Thiel D. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am J Gastroenterol 2002; 97:435-439.
19. Lee SD, Chan CY, Yu MI, Lu RH, Chang FY, Lo KJ. Hepatitis B vaccination in patients with chronic hepatitis C. J Med Virol 1999; 59:463-468.
20. Leroy V, Bourliere M, Durand M, Abergel A, Tran A, Baud M, et al. The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C viral load in patients with chronic hepatitis C: a case-control study. Eur J Gastroenterol 2002; 14:485-489.
21. Pontisso P, Ruvoletto MG, Fattovich G, Chemello L, Gallorini A, Ruol A, et al. Clinical and virological profiles in patients with multiple hepatitis virus infection. Gastroenterology 1993; 105:1529-1533.
22. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, et al. Characteristics of patients with dual infection by hepatitis B and C virus. J Hepatol 1998; 28:27-33.
23. Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus. Hepatology 1995; 22:1101-1108.